TP-3654 is currently being evaluated in a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with intermediate or high-risk primary or secondary myelofibrosis.
Based on a post hoc analysis, fewer required respiratory interventions
Efgartigimod is approved in the United States as VYVGART for the treatment of adults with generalized myasthenia gravis
TLANDO was approved by the U.S. Food and Drug Administration (FDA) on March 28, 2022.
Scemblix (asciminib) continues to show superior efficacy with more-than-two-fold improvement in major molecular response rate vs. Bosulif (bosutinib) at 96 weeks
82.5% of patients treated at 10mg dose of obicetrapib achieved LDL-c target of <70 mg/dL, compared to 20% of patients treated with placebo
he Phase 2 TIDAL data generated to date continue to highlight zandelisib's therapeutic profile and the potential to benefit patients
The company has launched indigenously produced Dual Chamber Bags of global standards in India at a pocket-friendly price
The dashboard will serve as a single source of truth for public and PM-JAY stakeholders providing comprehensive view of scheme’s progress
The companies will jointly identify and develop molecular glue degraders up to a clinical candidate stage.
Subscribe To Our Newsletter & Stay Updated
